Rogco LP Cuts Stake in Pfizer Inc. (NYSE:PFE)

Rogco LP trimmed its stake in Pfizer Inc. (NYSE:PFE) by 11.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 16,588 shares of the biopharmaceutical company’s stock after selling 2,241 shares during the quarter. Rogco LP’s holdings in Pfizer were worth $440,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. J.W. Cole Advisors Inc. boosted its holdings in Pfizer by 28.3% in the fourth quarter. J.W. Cole Advisors Inc. now owns 111,553 shares of the biopharmaceutical company’s stock valued at $2,959,000 after acquiring an additional 24,593 shares during the last quarter. Valmark Advisers Inc. raised its holdings in shares of Pfizer by 2.3% in the 4th quarter. Valmark Advisers Inc. now owns 41,716 shares of the biopharmaceutical company’s stock worth $1,107,000 after purchasing an additional 955 shares during the period. L.M. Kohn & Company lifted its stake in shares of Pfizer by 4.4% in the 4th quarter. L.M. Kohn & Company now owns 37,911 shares of the biopharmaceutical company’s stock valued at $1,006,000 after purchasing an additional 1,597 shares in the last quarter. Hourglass Capital LLC grew its holdings in shares of Pfizer by 42.1% during the 4th quarter. Hourglass Capital LLC now owns 397,720 shares of the biopharmaceutical company’s stock worth $10,552,000 after purchasing an additional 117,820 shares during the period. Finally, Secured Retirement Advisors LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $206,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE opened at $25.50 on Monday. The firm has a market cap of $144.48 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a fifty day simple moving average of $26.28 and a 200 day simple moving average of $27.56. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. The company’s revenue was up 24.7% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.75%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on PFE. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Guggenheim reaffirmed a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.